Ramifications of screening for breast cancer: Overdiagnosis in the Malmö trial was considerably underestimated

BMJ 2006; 332 doi: 10.1136/bmj.332.7543.727-a (Published 23 March 2006)
Cite this as: BMJ 2006;332:727.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Peter C Gøtzsche, director (pcg@cochrane.dk)
  1. Nordic Cochrane Centre, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark

    EDITOR—Updated results from the Malmö mammography screening trial have suggested that screening caused an over-diagnosis of breast cancer of 10% in women aged 55-69 years at randomisation.1 The authors noted that evidence from randomised trials on the level of overdiagnosis was lacking. This is not correct. On the basis of data from the Malmö trial,2 and the two trials from Canada,3 we have previously estimated a level of overdiagnosis of 30% (mean follow-up 8.8 years and 7 years, respectively)4 and have also suggested an over-diagnosis of 33% in …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL